541 related articles for article (PubMed ID: 8447359)
41. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
[TBL] [Abstract][Full Text] [Related]
42. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
43. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
44. The role of thromboxane A2 in increased whole blood platelet aggregation in oral contraceptive users.
Norris LA; Devitt M; Bonnar J
Thromb Res; 1996 Feb; 81(4):407-17. PubMed ID: 8907290
[TBL] [Abstract][Full Text] [Related]
45. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
46. Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells.
Quehenberger P; Kapiotis S; Pärtan C; Schneider B; Wenzel R; Gaiger A; Speiser W
Ann Hematol; 1993 Jul; 67(1):33-6. PubMed ID: 8392873
[TBL] [Abstract][Full Text] [Related]
47. [Hormonal contraception].
Van Cauwenberge JR
Rev Med Liege; 1992 May; 47(5):221-36. PubMed ID: 1604074
[TBL] [Abstract][Full Text] [Related]
48. A norgestimate-containing oral contraceptive: review of clinical studies.
Kafrissen ME
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
[TBL] [Abstract][Full Text] [Related]
49. Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel.
Basdevant A; Conard J; Pelissier C; Guyene TT; Lapousterle C; Mayer M; Guy-Grand B; Degrelle H
Contraception; 1993 Sep; 48(3):193-204. PubMed ID: 8222650
[TBL] [Abstract][Full Text] [Related]
50. [Side effects of third generation progestagens].
Sitruk-ware R
Contracept Fertil Sex (Paris); 1993 Apr; 21(4):295-300. PubMed ID: 12318229
[TBL] [Abstract][Full Text] [Related]
51. [Cardiovascular risks of oral contraceptives: dose-response relationship].
Kelleher CC
Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220
[TBL] [Abstract][Full Text] [Related]
52. Clinical review of a monophasic oral contraceptive containing desogestrel and ethinyl estradiol.
Stone S
Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():117-21. PubMed ID: 8260969
[TBL] [Abstract][Full Text] [Related]
53. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
[TBL] [Abstract][Full Text] [Related]
54. Effect of combined low-dose oral contraceptives on blood viscosity and haematocrit.
Ishak R; Loh Chooi Khim
Malays J Reprod Health; 1991 Jun; 9(1):5-8. PubMed ID: 12317443
[TBL] [Abstract][Full Text] [Related]
55. Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate.
Chez RA
Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1296-300. PubMed ID: 2524163
[TBL] [Abstract][Full Text] [Related]
56. Changes in the plasma levels of proteins C and S in young women on low-dose oestrogen oral contraceptives.
Granata A; Sobbrio GA; D'Arrigo F; Barillari M; De Luca P; Egitto M; Granese D; Pullè C; Trimarchi F
Clin Exp Obstet Gynecol; 1991; 18(1):9-12. PubMed ID: 1829030
[TBL] [Abstract][Full Text] [Related]
57. Effect of four combined oral contraceptives on blood pressure in the pill-free interval.
Nichols M; Robinson G; Bounds W; Newman B; Guillebaud J
Contraception; 1993 Apr; 47(4):367-76. PubMed ID: 8508666
[TBL] [Abstract][Full Text] [Related]
58. Effect of levonorgestrel contraceptive implants, Norplant, on blood coagulation.
Shaaban MM; Elwan SI; el-Kabsh MY; Farghaly SA; Thabet N
Contraception; 1984 Nov; 30(5):421-30. PubMed ID: 6440738
[TBL] [Abstract][Full Text] [Related]
59. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study.
Middeldorp S; Meijers JC; van den Ende AE; van Enk A; Bouma BN; Tans G; Rosing J; Prins MH; Büller HR
Thromb Haemost; 2000 Jul; 84(1):4-8. PubMed ID: 10928461
[TBL] [Abstract][Full Text] [Related]
60. Desogestrel versus gestodene in oral contraceptives: influence on the clinical and histomorphological features of benign breast disease.
Di Lieto A; De Rosa G; Albano G; Pagnano AM; Campanile M; Terracciano L; Pontillo M; Cimmino E; Covelli A; Paladini A
Eur J Obstet Gynecol Reprod Biol; 1994 May; 55(1):71-83. PubMed ID: 7958144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
